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1. Summary
The innate immune response is the first line of defence against infection.
Germ-line-encoded receptors recognize conserved molecular motifs from both
exogenous and endogenous sources. Receptor activation results in the initiation
of a pro-inflammatory immune response that enables the resolution of infection.
Understanding the inner workings of the innate immune system is a fundamen-
tal requirement in the search to understand the basis of health and disease. The
development of new vaccinations, the treatment of pathogenic infection,
the generation of therapies for chronic and auto-inflammatory disorders, and
the ongoing battle against cancer, diabetes and atherosclerosis will all benefit
from a greater understanding of innate immunity. The rate of knowledge acqui-
sition in this area has been outstanding. It has been underpinned and driven by
the use of model organisms. Information obtained from Drospohila melanogaster,
knock-out and knock-in mice, and through the use of forward genetics has
resulted in discoveries that have opened our eyes to the functionality and com-
plexity of the innate immune system. With the current increase in genomic
information, the range of innate immune receptors and pathways of other
species available to study is rapidly increasing, and provides a rich resource
to continue the development of innate immune research. Here, we address
some of the highlights of cross-species study in the innate immune field and
consider the benefits of widening the species-field further.
2. The beginnings of innate immunity
Without question, the immune system is an essential product of evolution. At
its most basic level, the immune response can be split into two arms: the
innate and the adaptive immune response. Innate immunity provides a non-
specific and generalized response to infection resulting in the induction of a
pro-inflammatory immune response. It is conserved across evolution and
found, in varying forms, in all multi-cellular organisms. In contrast, the adap-
tive immune response appears to be the prerogative of vertebrates and results in
the generation of specific protective immunity against pathogens. Adaptive
immunity also results in the generation of immunological memory, thereby
allowing a more rapid, and more robust, response to subsequent antigenic chal-
lenge. The two arms of the immune response are intrinsically linked with the
innate response influencing the development of adaptive immunity [1].
The concept of innate immunity as we know it was first proposed by
Charles Janeway in an address to the Cold Spring Harbor Symposium in
1989 [2]. Subsequent work by Jules Hoffman and co-workers in Strasbourg
led to the discovery of the first innate immune signalling receptor (pattern rec-
ognition receptor, PRR), Toll, in the fruitfly Drosophila melanogaster. They
demonstrated that the production of antimicrobial peptides in Drospohila
& 2012 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, provided the original
author and source are credited.depended on the induction of a signalling cascade via the
activation of the receptor Toll [3]. The identification of the
human homologue of the Toll protein (Toll-like Receptor 4,
TLR4) by Janeway’s group [4] paved the way for Bruce Beu-
tler and co-workers to show that the TLR4 protein was the
receptor for bacterial lipopolysaccharide (LPS) driving the
inflammatory response to endotoxin in mice [5]. Specifically,
they characterized a mutation, P712H, in the BB loop region
of the TLR4 cytoplasmic signalling Toll Interlekin-1 receptor
(TIR) domain of C3H/HeJ mice that rendered the mice resist-
ant to the effects of LPS [5]. The seminal nature of these
works and their subsequent impact on immunology was
recognized by the awarding of the 2011 Nobel Prize in Physi-
ology or Medicine to Jules Hoffman and Bruce Beutler, for
identifying PRRs, jointly with the late Ralph Steinman for
his discovery of dendritic cells [6]. The initial observations
regarding the similarities between the immune systems of
the fly and humans beautifully demonstrate the advantages
of cross-species biology in developing our understanding of
how the innate immune system works. The use of predomi-
nantly human, murine and Drosophila models has helped
facilitate the growth of our understanding of the innate
immune system at an unprecedented rate. In this paper, we
address some of the successes of cross-species research in
innate immunity, highlight some of the caveats, and provide
examples of where other, less mainstream, species have
already significantly benefited research in innate immunity.
3. Pattern recognition receptor: form and
function
PRRscanbebroadlyclassifiedintofivedifferentclasses:TLRs,
nucleotide-binding leucine-rich repeat-containing receptors
(NLRs), retinoic acid-inducible gene-I (RIG-I)-like receptors
(RLRs), C-type lectins (CTLs) and Absent-in-melanoma
(AIM)-like receptors (ALRs). Together these receptor families
provideanextensiverepertoireofdefencesentinelsresponsive
to activating ligands from exogenous sources, such as patho-
gens and allergens, as well as endogenous danger signals.
TLRs can be found in the plasma membrane, where they
detect a wide variety of lipid or protein-based ligands. TLRs
also reside in endosomal membranes, where they respond to
nucleic acids, providing a key element of the antiviral
response. CTLs are membrane-associated, albeit just on the
plasma membrane. CTLs generally recognize carbohydrate-
based ligands and are important sentinels for the detection
of fungal infections. The NLRs, RLRs and ALRs are cyto-
plasmic receptors. The NLRs characterized to date respond
to a variety of viral, bacterial and host-derived ligands. The
RLRs and ALRs respond to viral RNA and bacterial or viral
DNA, respectively. Hence, for many pathogens, a wide var-
iety of different receptors and their signalling pathways will
be simultaneously activated.
Receptor activation results in the induction of a
pro-inflammatory immune response. This response is charac-
terized and controlled by the production of pro-inflammatory
cytokines such as tumour necrosis factor alpha (TNFa), inter-
leukins (IL) -1 and -8, and interferon (IFN). The precise
combination and quantities of cytokines produced by PRR
activation will dictate the exact nature and severity of the
immune response. For example, IL-8 is a strong chemoattrac-
tant for neutrophils and type I IFNs help to promote cellular
defences against viral infection. IL-1 is a key mediator of
inflammation, and inhibition of IL-1 signalling is of major
interest for the treatment of many inflammatory and autoin-
flammatory conditions. Production of IL-1b during innate
immunity isthe prerogativeof the inflammasome. The inflam-
masome is a multi-protein complex formed by PRRs such as
NLRP3, NLRP1, NLRC4/NAIP (neural apoptosis inhibitory
protein) and AIM2. In most inflammasomes, the adaptor
protein ASC (apoptosis-associated speck-like protein contain-
ing a caspase activation and recruitment domain, CARD) is
used to recruit procaspase 1. Procaspase 1 undergoes sub-
sequent cleavage to release active caspase 1, which can then
process pro-IL-1b and pro-IL-18 to facilitate secretion of the
active cytokines from the cell. The detailed mechanisms of
PRR activation, their signalling cascades and the resultant
cellular effects have been widely reviewed [7–10].
Interestingly, there is marked variation in the range and
number of PRRs possessed by different species throughout
biology (table 1). Such variation underlies evolutionary press-
ures upon the developing immune system and may well be
indicative of the types of threats commonly experienced by
each species. Recent analysis of the evolution of the domain
architecture in TLRs and NLRs identified a highly complex
evolutionary history [11]. Zhang and co-workers concluded
that in addition to clear evidence of species-specific receptor
expansion, there has also been independent evolution of the
protein folds used by these receptors [11]. Independent evol-
ution across diverse species can lead one to assume that the
major range of protein domains used in the innate immune
system—LRR (leucine-rich repeat), CARD, PYD (pyrin
domain), NACHT (domain present in NAIP, CIITA, HET-E
and TP1), DD (death domain), TIR—provides the most
suitable tertiary structures for the required cellular functions.
The most notable variation in PRR repertoire occurs
between species with a divergent ancestry (table 1). Drosophila
possesses nine orthologues of the TLR pathway. Of these
only Toll itself has a fully confirmed role in innate immunity.
Toll-9 has been implicated, via a genome-wide expression
analysis, in the activation of innate immune signalling
pathways, and may also potentially contribute to innate
immunity in the fly. Activation of Drosophila Toll is through
binding to the endogenous ligand Spa ¨tzle. Mammalian
TLRs are primarily viewed as receptors for exogenous
molecules such as LPS, although there is an increasing
Table 1. The number of TLR and NLR family members varies between
species. The number in parentheses for teleost TLRs reﬂects the paralogues
identiﬁed in the Atlantic cod genome.
TLRs NLRs
Drosophila 90
human 10 22
murine 12 34
chicken 10 1
teleosts 17 (36) NLR-A–5
NLR-B–6
NLR-C-hundreds
purple sea urchin 222 203
amphioxus 71 118
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2repertoire of endogenous ligands that have been reported
[12]. Meanwhile, Caenorhabditis elegans has just a single TLR
orthologue, Toll family protein 1 (TOL-1), which appears
not to function in an innate immune capacity at all. Instead,
this function falls to the Toll/IL-1R (TIR) protein [13]. TIR
is homologous to the human SARM1 (sterile a-and arma-
dillo-motif-containing protein-1), although human SARM1
is a negative regulator of TLR signalling [14] rather than an
activator of innate immunity.
Of course, one must remember that some PRRs have
also had developmental roles identified either instead of or
in addition to their function in innate immunity. Indeed, the
prototype PRR, Drosophila Toll, is important in dorsal–
ventral patterning during embryogenesis. Similarly, Drosophila
Toll2 and Toll5–9 are all believed to have roles in development
[15]. For example, Toll8 is important for glycosylation in the
embryonic nervous system, while Toll2 has an important func-
tion incelladhesionandmigration duringlarvaldevelopment.
The mammalian TLR family have not as yet had any develop-
mental roles identified. In contrast, mammalian NLR proteins
appear to segregate, at least partially, into proteins with
immune functionsand proteins with developmentalfunctions.
NLRP2 may well be involved in epigenetic regulation and has
been associated with Beckwith–Widemann syndrome, a form
of foetal overgrowth; NLRP5 deficiency in the mouse results
in failure of the embryo to pass the two-cell stage; NLRP7
is associated with trophoblast development and may be lin-
ked with neonatal growth disorders and termination;
whereas NLRP14 is expressed at high levels in human testes
and is also found in murine ovaries (reviewed by Kufer &
Sansonetti [16]).
4. Pattern recognition receptor conservation
and diversification across species
In comparison with mammals, some species have undergone
PRR expansion. Analysis of the sea urchin genome has ident-
ified 222 TLR-like and 203 NLR-like genes. The observation
of NLR-like genes in the sea urchin Strongylocentrotus led to
a reconsideration of the evolutionary beginnings of the
NLR family [17–19]. Previously, the absence of NLR family
members in either Drosophila or C. elegans [20] had led to
the view that the evolutionary origin of the NLR family
resided with the teleost fish. However, the presence of tripar-
tite NLR-like proteins in the sea urchin and other anthozoan
cnideria [21] demonstrates an earlier evolutionary origin. It
now appears plausible that evolutionary precursors of the
NLR family exist in basal metazoans. Recent reports of poten-
tial NACHT–LRR genes in mosquitoes and freshwater
crustaceans suggest that the NLRs may indeed be present
in ecdysozoans [21]. Of course, one must also remember
that the NLR proteins bear a marked similarity to the plant
disease resistance (R) proteins, in terms of both domain
organization and function [22]. However, rather than
suggesting that eukaryotic cells possessed a common ances-
tral gene prior to the splitting of animal and plant lineages,
it appears that the similarity of the NLR and R proteins is
the result of convergent evolution [20].
Teleost fish have, to date, had 17 distinct members of the
TLR family identified [23]. Some of these are homologous to
mammalian TLRs; however, seven of them appear distinct
to the teleost. A number of members of the teleost family
show evidence for the presence of paralogues. This is most
apparent in the recently sequenced Atlantic cod [24]. Here,
five paralogues are observed for each of TLR7, 8 and 9, and
eight paralogues for TLR22. The basis of this expansion is
unknown, but one could hypothesize that it reflects a need
to respond either more robustly to a specific subset of patho-
gens or to a requirement for subtle differentiation between
similar activatory ligands. The teleost fish have orthologues
of both the NLRC and NLRP subfamilies. In addition, they
also encode a unique teleost-specific subfamily containing
hundreds of receptors, NLR-C [25]. The NACHT domain of
the teleost NLR-C subfamily is most closely related to the
mammalian NLRC3 NACHT. However, the N-terminus of
the teleost proteins contains a range of effector domains,
including Pyrin domains, which suggests a diverse down-
stream signalling network. Unlike other NLR proteins, the
teleost NLR-C subfamily members contain a B30.2 protein
interaction domain downstream of the LRR domain. The func-
tional role of the B30.2 motif has yet to be elucidated, but is
likely to diversify the range of proteins with which these
NLR-C subfamily members can interact. This in turn may
well enhance the functionality of the receptors by enabling
the activation of awider range of cellular signalling pathways.
It may also help facilitate receptor cross-talk. Understanding
the mechanisms of activation and signalling of the teleost
PRRs will be enlightening, and the innate immune repertoire
of the teleosts is rapidly being characterized [26].
Other vertebrates also display different PRRs to those
found in mammals. This is exemplified by the chicken. The
chicken possesses orthologues of TLR3, 4, 5 and 7; in addition,
it also encodes for both TLR1 and TLR2. However, both
chicken TLR1 and TLR2 are present as two paralogues that
result from gene duplications from the TLR1/6/10 and
TLR2 family of vertebrate receptors [27]. Two additional
TLRs are also found in the chicken—TLR15 and TLR21.
TLR21 seems shared between birds and fish, and in chickens
is a TLR9 orthologue [28]. TLR15 has to date only been
found in the avian population [29] and is one of the most poly-
morphic TLRs in the avian repertoire, along with avian TLR5
[30]. As yet the precise ligand for TLR15 has not been ident-
ified, but it is known to be bacterial in origin [31]. This is a
good example of why cross-species biology continues to fasci-
nate—what does avian TLR15 respond to? What does this tell
us about the development and pressures of the avian innate
immune system? And how, if at all, does it relate to the
spread of zooanotic infections relevant to both animal and
human health? Identification of the ligand for chTLR15 will
require experimental clarification, but one could hypothesize
that it may well show a degree of specificity for bacterial
species commonly encountered by the chicken. In fact, the
presence of TLR15 in the chicken, coupled with the loss of
other TLRs found in mammals, may well be an example of
evolution in action and reflect the range of pathogens associ-
ated with the chicken. A similar rationale could be provided
to the expansions of PRRs in the sea urchin and NLRs in the
teleost fish—the aquatic pathogen repertoire will be much
different to that routinely encountered by mammals.
Even within mammals, we see clear differences in PRR
possession. For example, humans have 10 TLRs and 22
NLRs, whereas mice have 12 and 34, respectively (table 1).
Within the NLR family NLRP1, NLRP4, NLRP9 and NAIP
all appear to have undergone expansion in rodents. In con-
trast, NLRP8 and NLRP13 have been lost from the rodent
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3genome, while NLRP11 appears to be primate-specific [32].
AIM2 has only been reported in primates and rodent species
[33]. A putative AIM2 gene has been identified in the equine
genome, but not, at present, in other mammalian genomes.
The limited distribution of AIM2 leads to the obvious
question of why specific innate immune pathways develop
in some closely related species but not in others. Dogs pos-
sess multiple mutations in their gene for NLRC4, a PRR
that recognizes a number of bacteria, which result in the
insertion of premature stop codons and a dysfunctional
receptor [34]. The evolutionary pressures, or lack of, which
have driven such mutations are unknown, but one can pre-
sume that pathogen exposure plays a role. Clearly, there is
extensive variation in PRRs across species, and data from
comparative work may well reveal important information
about pathogen host specificity and evolutionary biology.
5. Structures and species
Determination of the molecular structure of pattern recog-
nition receptors has proved to be difficult. Only in the last
few years have we begun to understand the molecular detail
involved in ligand recognition for the TLRs with the gradual
solving of the apo- and ligand-bound forms of a selection of
TLR ectodomains (figure 1). This began in 2005 when the
apo-form of human TLR3 was solved independently by two
separate research groups [35,36]. These structures provided
human apo-TLR3
(PDBs 1ziw, 2a0z)
human TLR4: VLR hybrids
(+MD2 + Eritoran)
(PDBs 2z62, 2z63, 2z65, 2z66)
human TLR2: VLR hybrids
human TLR1:TLR2 heterodimer + 
Pam3CSK4
(PDBs 2z80, 2z7x)
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murine TLR4 + MD2
(PDB 2z64)
murine TLR3 + dsRNA
(PDB 3ciy)
zebrafish apo-TLR5 and zebrafish
TLR5 + flagellin (PDBs 3v44, 3v47)
murine TLR2: TLR6
VLR hybrid heterodimer
( + PAM2CSK4)
(PDB 3a79))
human TLR4 + MD2 + LPS
(PDB 3fxi) murine TLR2:
VLR hybrids
(+ synthetic ligands)
(PDBs 2z81, 2z82)
murine TLR2:
VLR hybrids
(+ ligands)
(PDBs 3a7b, 3a7c))
Figure 1. Timeline of TLR ectodomain structural characterization. The list to date of current structures of TLR ectodomains from humans, mice and zebrafish are
shown in conjunction with their Protein Data Bank (PDB) identifies. Murine and zebrafish structures are presented in ribbon format and images were generated using
the PYMOL molecular graphics system, v. 1.3, Schro ¨dinger, LLC. Years highlighted in bright blue (2006, 2010, 2011) correspond to those in which no TLR ectodomain
structures were published. PDB files are associated with the following references: PDB 1ziw [35]; PDB 2a0z [36]; PDBs 2z62, 2z63, 2z64, 2z65, 2z66 [37]; PDBs 2z80,
2z81, 2z82, 2z7x [38]; PDB 3ciy [39]; PDB 3fxi [40]; PDBs 3a79, 3a7b, 3a7c [41]; and PDBs 3v44, 3v47 [42]. VLR, variable lymphocyte receptor.
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4the first experimental confirmation that the TLR LRR ectodo-
main did indeed form the type of solenoid-like structure that
hadbeen predicted. Producingsufficient quantitiesof purified
protein for structural characterization has proved to be an
arduous task for these proteins. It was another 2 years before
any further TLR ectodomain structures were published.
These were made feasible by the development of J.-O. Lee’s
work using variable lymphocyte receptor (VLR) capping tech-
niques [43]. The VLR is an LRR-containing protein involved in
the adaptive immune response of the sea lamprey. Following
from the successful structural characterization of the VLR
itself [44], the inspired approach of adding VLRcapping struc-
tures onto the N- and C-termini, either individually or in
parallel, of TLR ectodomains was initiated. This was feasible
owing to the similar repeat size and consensus sequence
betweenVLRsand TLRs[43,45].Theuse ofVLRcapping tech-
nology has to date facilitated the high-resolution crystal
structures of: human TLR4 in complex with MD2 and the
antagonist Eritoran [37]; human and murine TLR2 in complex
with various ligands [38,41]; a human TLR2:TLR1 heterodimer
[38]; a murine TLR2:TLR6 heterodimer[41]; and,most recently,
zebrafish TLR5 in complex with flagellin [42]. Interestingly, the
structure of the active complex of TLR4:MD-2:LPS was solved
without the need for VLR capping [40]. These structures pro-
vide a fantastic example of how merging protein sequences
from different species can result in a hybrid protein conducive
to downstream analysis, thereby significantly enhancing our
biological understanding of TLR activation.
Solving the structures of murine, in addition to human
PRRs is particularly enticing for two main reasons. First, a
large proportion of PRR functional work is performed in
murine cells. Second, the sequence identity between murine
and human proteins is sufficient for the resultant structures
to be highly similar. Consequently, they provide an excellent
framework for understanding the molecular basis of receptor
function in the absence of human information. This is high-
lighted by the structural similarities between the murine
and human receptors of TLR3 and TLR4 (figure 2 and
table 2). In fact, the TLR3 structures are so similar that the
observed root mean square deviation of either of the solved
human apo-TLR3 structures with the murine ligand-bound
structure [39] is comparable to that between the two human
structures (table 2).
Other species are now being used for the determination of
PRR molecular structures. As mentioned above, the crystal
structure of zebrafish TLR5 in complex with the D1/D2/D3
fragment of Salmonella flagellin has just been solved [42]. Inter-
estingly, during this work, Yoon and co-workers screened
TLR5 from humans, mice, frogs, trout and zebrafish, but only
the zebrafish construct resulted in the production of secreted,
soluble protein in a baculovirus expression system. To generate
sufficient quantities of protein for structural studies required
subsequent addition of VLR capping structures.
Various domains of RIG-I have had their structures
solved, both in the presence and absence of ligand [46]. How-
ever, the full-length receptor and the CARD domains had
remained refractive to crystallization. This was recently
resolved through utilization of RIG-I from Anas platyr-
hynchos, the mallard duck [47]. Duck RIG-I is 53 per cent
identical to the human protein and shows good similarity
in overall architecture of the protein in comparison with
the human structures. This work has provided insight into
the nature of RIG-I repression in the absence of ligand
activation. CARD1 and CARD2 interact in a head-to-tail
manner as a single unit. CARD2 subsequently binds to the
helicase insertion domain, thereby inhibiting the binding of
the RIG-I helicase domain to its double-stranded RNA
ligand. It is postulated that this positioning of the CARD
(a)
(b)
Figure 2. Murine and human TLR ectodomain structures are nearly identical.
(a)Overlayoftheectodomainsofmurine TLR3(PDB3ciy,red)andbothhuman
TLR3 structures (PDB 2a0z, orange; PDB 1ziw, blue). (b) Overlay of the human
(PDB 2z63, blue) and murine (PDB 2z64, red) ectodomains of TLR4. Structures
are shown in a ribbon representation. Images were generated using the PYMOL
molecular graphics system, v. 1.3, Schro ¨dinger, LLC.
Table 2. Root mean square deviations (r.m.s.d.) of murine and human
TLR ectodomain structures. The PDB code of each molecule is given
in parentheses.
molecule A molecule B r.m.s.d (A ˚)
human TLR3 (1ziw) murine TLR3 (3ciy) 1.078
human TLR3 (2a0z) murine TLR3 (3ciy) 1.521
human TLR3 (2a0z) human TLR3 (1ziw) 1.083
human TLR4 (2z63) murine TLR4 (2z64) 2.147
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5domains hinders the access of accessory proteins required to
ubiquitinate RIG-I and facilitate signalling. Ligand binding
by the C-terminal domain subsequently assists in the co-
operative binding of ATP and double-stranded RNA to the
helicase domain, the release of the CARDs, and the activation
of RIG-I signalling [47]. Given the recent successes of zebra-
fish TLR5 and duck RIG-I, it is highly likely that a wider and
more diverse range of species will be screened for permis-
siveness and suitability to structural studies in the next few
years as more research groups try to resolve the molecular
basis of innate immune function. This is particularly likely
for receptors with little or no structural information, such
as the NLRs.
6. Variation in ligand specificity between
species
It is common knowledge that not all species respond to
pathogen infections in the same way. This may relate to, for
example, the site of infection, the symptoms that manifest,
the severity of disease, the duration of infection, the
host–pathogen relationship, the extent of the immune
response, and the precise role of different ligands as agonists
and antagonists.
The variation in the innate immune responses of different
species to different ligands is beautifully highlighted by three
different PRRs—TLR4, the NLRC4:NAIP inflammasome and
NOD1. In the case of TLR4, which in conjunction with MD-2
responds to LPS [48], fascinating observations have been
made regarding the different agonistic and antagonistic be-
haviour of ligands when recognized by human, mouse and
horse forms of the receptor. The lipid A portion of Escherichia
coli LPS is sufficient to induce TLR4:MD-2 activation. Lipid A
molecules vary in the number and length of the acyl chains
present, both as part of the biosynthetic pathways involved
in lipid A production and also between the different types
of lipid A produced by different bacterial species. This
change in lipid A structure affects its immunostimulatory
properties. For example, E. coli lipid A is primarily hexa-
acylated and a strong receptor agonist across species. Yersinia
pestis, the causative agent of plague, switches its Lipid A
from an immunostimulatory hexa-acylated form to a non-
stimulatory antagonistic tetra-acylated form at 378C—a
process that is believed to be an immune evasion strategy
[49]. Different types of lipid A also induce different
immune responses dependent on the species of receptor
being activated. For example, the penta-acylated lipid A
from Rhodobacter sphaeroides is an agonist in horses, and an
antagonist in humans and mice [50]. Similarly, tetra-acylated
lipid IVa from E. coli functions as an agonist in horses
and mice, but as an antagonist to human TLR4:MD-2
activation [51,52].
Sequence variations in TLR4 and MD-2 between species
can help explain the molecular basis of the species differences
in TLR4:MD2 response to lipid A stimulation. For example,
specific regions of horse MD-2 (residues 57–107) and horse
TLR4 (LRR14 – 18) are required for the agonist activity of
lipid IVa [52]. Furthermore, the agonistic activity of lipid
IVa upon equine TLR4:MD-2 was lost when arginine 385 in
equine TLR4 was mutated to a glycine, the equivalent
human residue. When the crystal structure of human TLR4-
MD2 and hexa-acylated lipid A was solved, it became
apparent that the lengthy arginine sidechain could poten-
tially stabilize the 1-phosphate group of lipid IVa, thereby
enabling agonistic behaviour [40]. This story helps highlight
how the combination of functional and structural
studies from different species can provide essential insight
into the mechanism of innate immune function. Zebrafish
TLR4 appears not to respond to LPS, but instead negatively
regulates NFkB signalling [53]. Should this be the case, it
will be an interesting addition to the species-specific reper-
toire of TLR4 receptors that are helping to improve our
understanding of the recognition of different types of bac-
terial LPS. Structural information derived from complexes
of species-specific signalling receptors with their appropriate
ligand will be important in explaining these data and will
also aid the design of compounds to modulate TLR4 activity.
It is not just classical lipid-based TLR4 activation that
shows species variation. TLR4 has also been implicated in
the hypersensitivity reaction to the metal nickel [54]. Two
histidine residues, H456 and H458, in the human TLR4 ecto-
domain are capable of inter-chelating with Ni
2þ atoms,
thereby activating the receptor in a lipid-independent
manner and contributing to the induction of hypersensitivity.
The murine TLR4 ectodomain lacks these two histidines
and, as a consequence, mice do not experience nickel
sensitization [54].
The NLRC4:NAIP inflammasome provides an intriguing
tale of species-specific behaviour in PRR biology. NLRC4 is
a member of the NLR family that possesses an N-terminal
CARD effector domain and forms an inflammasome complex
that activates caspase 1 in response to stimulation with flagel-
lin or type III secretion system proteins such as PrgJ from
Salmonella [55,56]. Recently, the NAIP (also known as NLRB
and Birc1; figure 3) proteins have been identified as a
second group of NLR proteins involved in the formation of
the NLRC4 inflammasome. It had been known for a while
that murine NAIP5 was important for the control of, and
immune response to, flagellin from Legionella pneumophila
hNAIPfull
hNAIP1
hNAIP2
hNAIPAlu
mNAIP1
mNAIP2
mNAIP3
mNAIP4
mNAIP5
mNAIP7
mNAIP6
Figure 3. Predicted domain organization of NAIP proteins from different species.
Red oval, BIR domain; blue rectangle, NACHT domain; lilac diamonds, LRR domain.
Domain information derived from Ting et al. [57] and Romanish et al.[ 5 8 ] .
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6[59–61]. Subsequently, the groups of Vance and Shao have
shown that different murine NAIP proteins provide the mol-
ecular basis for detection of specific ligands and signal
through the formation of an inflammasome in conjunction
with NLRC4 [62,63]. Specifically, murine NAIP2 is required
for the detection of type III secretion components, while
either murine NAIP5 or murine NAIP6 are capable of
responding to flagellin. As yet the ligands, should there be
any, detected by the remaining four mice NAIP proteins
have not been identified. Murine NAIP3 and NAIP4 are
reported to contain only baculoviral inhibition of apoptosis
protein repeat (BIR) domains [57] and therefore may have a
regulatory role, rather than one involved in detection.
It is currently difficult to directly relate the observations
regarding the role of murine NAIPs to humans. The human
genome contains one full-length gene for human NAIP and
four partial deletions. While only a single full-length protein
is believed to be expressed in human cells, various human
NAIP isoforms have been detected as a result of the use of
internal and upstream transcription start sites [58] (figure
3). The functionality of these isoforms remains unknown.
What is clear is that humans do not possess clear orthologues
of murine NAIP2, 5 and 6. Does human NAIP substitute for
all of the functionality of murine NAIP2, 5 and 6? Certainly,
we know that human NAIP has a role in the defence against
Legionella pneumophila [64] and may therefore be able to
mirror the role of murine NAIP5. Human NAIP has been
shown to respond to the type III secretion apparatus of a var-
iety of bacteria. However, it appears to be activated by the
needle proteins rather than the rod proteins that stimulate
murine NAIP2 [63]. The molecular basis of this specificity
is as yet unknown. The functionality of the human
NAIP:NLRC4 inflammasome and the role of human NAIP
in the specificity of ligand detection remains a key unan-
swered question. Consequently, at least for now, one must
be cautious in drawing parallels between the role of murine
and human NAIP proteins. It will be intriguing to see how
our understanding of the functionality of human NAIP
develops. In addition to primates and rodents, NAIP ortholo-
gues have been identified in cows, horses and frogs. It may
well be that the study of NAIP proteins from a wider range
of species is required to fully understand the role of this
PRR in innate immunity.
NOD1 is another member of the NLR family. Like
NLRC4, it also possesses an N-terminal CARD effector
domain. However, NOD1 responds to fragments of peptido-
glycan from Gram-negative bacteria that contain a
diaminopimelic acid moiety [65]. NOD1 does not form an
inflammasome. Instead, it engages the CARD-containing
kinase receptor interacting protein 2 (RIP2), resulting in
the activation of NFkB responsive genes and the secretion
of pro-inflammatory cytokines such as IL-8. Early studies
on the receptor demonstrated that a while a tripeptide
stem length is the optimal size for stimulating human
NOD1, murine NOD1 is preferentially stimulated with a tet-
rapeptide stem length [66]. Although other lengths of
peptide stem still activate the receptor, the proficiency of
this response is reduced. In a follow-up study, mutagenesis
identified the region most likely to be responsible for this
species variation in optimal ligand length to a region
around amino acids 816 and 844 [67]. In particular,
mutation of the glutamic acid at position 816 in human
NOD1, to either a serine or an aspartic acid (as found in
the mouse), led to improved activation by the synthetic
ligand FK156, consistent with the preference of murine
NOD1. NOD1 from the pig, which, like the human
sequence, has a glutamic acid at residue 816, shows a pat-
tern of ligand responsiveness more closely matched to that
of human NOD1 [68]. Comparative studies of NOD1 from
a variety of species may help clarify the exact role of specific
amino acids in the process of ligand recognition.
7. Inflammatory models of disease
Model systems are an essential part of immunological inves-
tigation. They provide a relatively accessible toolbox with
which to probe our understanding of the genetic and molecu-
lar basis of immune signalling. Without question, they have
contributed, and continue to contribute, extensively to our
understanding of the human immune system. Both the fly
and mouse were crucial in the early characterization of the
immune system. Murine studies in particular have continued
to expand our knowledge regarding the composition and
functionality of the immune signalling pathways. Forward
genetics and the generation of knock-out mice have enabled
the precise role of individual components of the immune
system to be determined. For example: the recognition of
TLR9 as the cellular receptor for bacterial DNA [69]; the criti-
cal role of MyD88 in interleukin signalling [70]; the in vivo
role of TLR2 [71]; the identification of the TLR adaptor
protein TRIF [72]; the importance of NAIP5 for resistance to
Legionella pneumophila infection [60]; and the importance of
TLR9 in the sensing of unmethylated DNA as a protection
against viral infection [73].
Studies in the mouse can be extremely enlightening, but
they are not humans, and there are many differences in the
immune systems, and therefore many limitations to mouse
studies. The PRR make up of mice differs from that of
humans (table 1). This will influence their response to
pathogens and ligand stimulation, as well as the cross-
talk and redundancy between PRR signalling pathways.
The possession of additional paralogues (e.g. NAIPs,
NLRP1, NLRP4 and NLRP9) complicates the generation
of knock-out models, but also the interpretation of results
and the direct relevance of inferred cross-species function.
Even cases where receptor expression and copy number
are identical may prove to be more complex. For example,
both mice and humans express TLR8. In humans, TLR8
responds to small synthetic ligands such as imiquimod
and R848, as well as single-stranded RNA. Murine TLR8,
however, was believed to be non-functional owing to its
failure to respond to similar ligands. This changed when
Gorden and co-workers demonstrated that murine TLR8
transfected into HEK cells was indeed functional, but
appeared to require a combination of polyT oligonucleo-
tides and a small molecule human TLR8 agonist such as
3M-002 or 3M-003 (which also stimulates TLR7) [74].
More recently, the functionality of murine TLR8 has been
further characterized by the observation that it mediates
detection of poly (A)/T-rich DNA by plasmacytoid dendri-
tic cells during poxviral infection [75]. A computational
comparative analysis of TLR8 models from human,
bovine, porcine, rat and mouse has now suggested a mol-
ecular basis for the inability of rodent TLR8 receptors to
signal in response to small molecule ligands [76]. This
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7analysis suggested not that rodent TLR8 was unable to
bind to ligands such as R848, but that instead the affinity
of interaction would be insufficient for activation of the
receptor. Poly (A)/T-rich DNA consequently provides a
specific role in enabling activation of rodent TLR8. The
basis of this behaviour is hypothesized to relate to the pre-
dicted electrostatic charge differences in the region between
LRRs 14–17 between species. This region includes a region
of undefined structure. This undefined region shows poor
sequence similarity between non-rodent TLR8s and may
account for some of the differences seen in ligand speci-
ficity between these species [76]. It remains to be seen
whether these observations will require the re-evaluation
of models in which murine TLR8 was assumed to be
non-functional.
Interestingobservationshaverecentlybeenmadeinrelation
to disorders in the cryopyrin-associated periodic syndromes
(CAPS) spectrum of diseases. CAPS are characterized by
three major diseases: familial cold auto-inflammatory syn-
drome (FCAS), Muckle-Wells syndrome (MWS) and
neonatal–onset multi-system inflammatory disease (NOMID).
Each of these autoinflammatory conditions results from the
presence of polymorphisms in the NLR-family member
NLRP3. Numerous polymorphisms have been linked with
these diseases. Some of these mutations in humans are linked
to just a single disease phenotype (for example, L353P and
FCAS, A352V and MWS). Others associate with multiple phe-
notypes, such as R260W, which is linked with both FCAS
and MWS. These polymorphisms result in constitutive acti-
vation of the NLRP3 inflammasome, caspase-1 processing,
and secretion of IL-1b and IL-18. In humans, the diseases
become more severe in the order FCAS, then MWS and finally
NOMID. Recently, the first murine models of CAPS have been
generated for mice with the mutations equivalent to human
R260W, A352V and L353P [77,78]. These mice have provided
the first opportunity to study the mechanistic basis and clinical
changes associated with these diseases away from the use of
patient-derived samples. The mice strains exhibited a more
severe disease phenotype than humans overall, but without
manifesting all human symptoms. These included inhibited
growth, cutaneous lesions, abscesses and dermal thickening.
Disease in the mice was shown to drive a T helper 17-type
response and to be partially dependent on IL-1b, and hence
inflammasome activation. Interestingly, the IL-1b dependence
was less extensive than would have been predicted given the
success of IL-1 inhibitors in treating CAPS [77,78]. This may
reflect underlying differences in the murine and human mani-
festations of the diseases. It certainly causes one to consider
how accurately observations in the mouse can be mapped
onto the human patient. A related and intriguing observation
is that in the work of Brydges and co-workers [78], the severity
of murine disease showed a reversed order in comparison with
humans CAPS. In humans, MWS is more severe than FCAS.
However, mice harbouring the FCAS-specific knock-in
showed a disease phenotype more severe than those harbour-
ing the MWS-specific mutation. MWS-specific mice generally
displayed symptoms at, or within, a day of birth, while the
FCASmutationusuallyledtoperinatalorintrauterinelethality.
The increased severity of these diseases in the mouse, and par-
ticularly the reversal in relative severity, raise some interesting
questions,suchas:howconservedisthestructuralenvironment
of the mutation? Are there different co-factors recruited to
human and murine inflamamsomes? Does the mechanism of
inflammasome regulation, and auto-activation, differ between
species? Are there other significant contributory factors to the
pathology of CAPS? What underlies the molecular basis of
this species-specific difference in disease phenotype remains
unknown, and realistically requires structural information
regarding the specific molecular environments of these
mutations in both the mouse and human. In addition, an
increased understanding about protein and/or co-factor inter-
actions around the polymorphisms may assist in the
unravelling of this observation.
The reversed phenotype of the CAPS mice, and the clear
difference in the extent of response to IL-1 antagonism, high-
lights that while such models can clearly provide an
unparalleled resource, the information obtained must be care-
fully analysed in light of species-specific differences. This is of
particular relevance in the development of therapeutics
against inflammatory conditions where modulation of the
immune system is critical.
8. Final comments
The rapid development of our understanding of the function-
ality of the innate immune system could not have been
predicted. It continues to advance at an awe-inspiring rate
and the complexities of the system are only now beginning
to become apparent. The regulation, the redundancy, the
cross-talk, the increasing receptor repertoire, the contribution
to adaptive immunity—these are just some of the major areas
of ongoing development. Species-specific research has under-
pinned many of the scientific advances in this field over the
last 20 or so years. Without question, we would not have
such a clear understanding of the basis of innate immune
functionality without the work performed on both the fly
and the murine innate immune systems. Of course, humans
are neither flies nor mice, and consequently, while in many
cases these studies provide accurate and informative
interpretation, we must always keep in mind that our
immune systems do not function in precisely the same way
as these other organisms.
With the increase in genome-sequencing projects, the
information available on innate immune components in
other species is rapidly expanding. This is a rich vein of infor-
mation and we need to ensure that it does not simply become
consigned to an electronic repository and forgotten. As yet,
there is no concerted effort to curate the immune genes in
these non-mainstream species, and we are reliant upon the
valuable work of small groups of researchers specifically
interested in subsets of genes for our increased understand-
ing of their function. In addition, it will require time to
enable the development of species-specific tools and reagents
to facilitate comprehensive characterization of immune genes
in non-model organisms. However, to date, we have only
explored a small fraction of the available species pool. Who
knows what marvels will be uncovered, and from what
sources, in the near future?
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